Small Biotechs often have a reputation for over-promising, exaggerating results and pumping the SP with unnecessary announcements.
Not MSB.
If anything their conservative approach attracts criticism for under-promoting their potential and achievements.
So when MSB releases a statement as they did this morning - it carries more weight than most.
It's still a long-shot imo - but it's a legitimate shot.
Gilead vs Mesoblast, page-2
-
- There are more pages in this discussion • 273 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |